The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.
Mitsukuni Suenaga
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Kiyohiko Hatake
No relevant relationships to disclose
Toshiharu Yamaguchi
No relevant relationships to disclose